Turnover: 53.7 billion EUR (2022)
Country: Germany
Description: Of German origin, Bayer opened its first pharmaceuticals department in 1888, 25 years after it was founded. Thirty percent of the Bayer Group's sales come from its healthcare subsidiary, with leading products in the anticoagulant (Xarelto) and anticancer (Stivarga, Xofigo) markets
Bayer has been expanding its presence in the herbal medicine market since the early 2010s, thanks to the acquisition of Steigerwald in 2013. Steigerwald specializes in analgesic, anti-inflammatory and digestive products such as Iberogast. Created in the late 1950s, Iberogast, composed of 9 essential plants, was distributed in 30 countries in 2013, enabling Bayer to invest significantly in the herbal medicine market
The Consumer Health division generated sales of 159.4 million euros in 2019, or 12.1% of total sales. This division covers vitamins and minerals, dermatological care and treatment, gastroenterology, phytotherapy, analgesia and women's intimate health
Bayer's range of herbal medicines focuses on two main products: Euphytosis night and day
News
Chemicals in the midst of a recovery, Bayer considers spin-offs 09/11/2023
- Bayer sales: Close to 50 billion euros.
- Date on which Bayer will make a decision on the demerger of its entities: March 2024.
- Loss of value of the Bayer Group in five years: 40%.
- Bayer weighed down by falling glyphosate sales
Bayer's glyphosate sales plummet 25/07/2023
- Full-year sales for the current financial year are forecast at between 48.5 and 49.5 billion euros.
- Bayer acquired the US group Monsanto in 2018 for over 63 billion euros.
- Bayer shares have lost half their value since 2018.
Financial Data
DUNS: 562038893
Legal Name: BAYER SAS
Address: 16 RUE JEAN MARIE LECLAIR , 69009 LYON 9EME
Number of employees: 103824 (2020)
Capital: 112 539 893 EUR
Financial Data:
| Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
|---|---|---|---|---|
| 2019 | 1 311 193 770 EUR | 182 088 868 EUR | 31/12/2019 | 12 |
| 2018 | 1 390 573 040 EUR | -4 202 198 EUR | 31/12/2018 | 12 |
| 2017 | 1 411 796 358 EUR | 193 919 768 EUR | 31/12/2017 | 12 |
| 2016 | 1 535 942 307 EUR | 105 784 883 EUR | 31/12/2016 | 12 |
| 2015 | 1 709 505 879 EUR | 76 905 988 EUR | 31/12/2015 | 12 |
Studies mentioning this company
The herbal medicine market - France
Other companies mentioned:
- Arkopharma
- Bayer
- Ipsen
- Santé Verte
- Merck KGaA
- Nutreov Physcience
- PiLeJe
- Fenioux Groupe
- NaturHouse
- Puressentiel France
- Pranarôm (Inula Groupe)
- Naturactive (Pierre Fabre)
- Olisma
- Densmore (Havea Groupe)
- Herbalife
- Institut Endobiogénie
- Atlantic Nature
- Olisma
The food supplements market - Italy
Other companies mentioned:
- Pfizer
- Sanofi Aventis
- Bayer
- Labocast
- Biofarma
The market for disinfection, disinsectisation, rodent control - France
Other companies mentioned:
- Ecolab
- Rentokil Initial
- Elis Groupe
- Avipur
- Anticimex
- JG Pest Control
- Killgerm
- As de Pic
- A3S
- APA
- AC2000
- Eficium
- Anolys
- Tech-Way
- A3DS
- Abioxir
- A2DEF
- Paredes Orapi
- BASF
- Bayer
- Germitec
- Lodi Group
- FC Johnson
- Sodel
The market of pharmacies - Germany
Other companies mentioned:
- Bayer
- Merck KGaA
- Johnson & Johnson
- Novartis
- Roche Groupe
- Rossmann
- dm
- Müller
- Amazon